You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommend venetoclax and azacytidine for patients with aggressive blood cancer

Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.